Agenus (NASDAQ:AGEN) Earns Buy Rating from Chardan Capital

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a note issued to investors on Thursday, Benzinga reports.

A number of other brokerages have also recently commented on AGEN. HC Wainwright restated a “buy” rating and set a $25.00 price target (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. Wall Street Zen cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. Rodman & Renshaw initiated coverage on shares of Agenus in a research note on Monday, September 28th. They set a “buy” rating and a $19.00 price target for the company. Weiss Ratings raised shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.50.

Agenus Stock Down 0.2%

AGEN traded down $0.01 during midday trading on Thursday, reaching $6.39. 191,073 shares of the company’s stock were exchanged, compared to its average volume of 1,875,229. The firm has a market capitalization of $288.59 million, a price-to-earnings ratio of 2.48 and a beta of 1.31. Agenus has a one year low of $2.71 and a one year high of $10.31. The business has a 50-day simple moving average of $7.71 and a two-hundred day simple moving average of $5.48.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The business had revenue of $34.52 million for the quarter, compared to the consensus estimate of $34.00 million. Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. As a group, research analysts anticipate that Agenus will post -0.30 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Everhart Financial Group Inc. acquired a new position in shares of Agenus during the third quarter worth approximately $100,000. Globeflex Capital L P bought a new stake in shares of Agenus during the second quarter worth $1,281,000. Bank of New York Mellon Corp acquired a new position in shares of Agenus during the second quarter valued at $311,000. Finally, Bank of America Corp DE lifted its stake in shares of Agenus by 796.7% during the first quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 105,536 shares during the period. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers.